Lundbeck
Article
Lundbeck is a recurring brand in the Astral Codex Ten archive, appearing 2 times across 2 issues between May 18, 2022 and May 31, 2023. The archive places it in contexts such as “gotten money from Lundbeck”; “a Danish team affiliated with the pharma company Lundbeck discovered an entirely new way to get into fights about this”. It most often appears alongside benzodiazepines, ADHD, Angelini.
Metadata
- Category: Brands
- Mention count: 2
- Issue count: 2
- First seen: May 18, 2022
- Last seen: May 31, 2023
Appears In
- Lavender’s Game: Silexan For Anxiety
- All Medications Are Insignificant In The Eyes Of God And Traditional Effect Size Criteria
Related Pages
-
- benzodiazepines (2 shared issues)
-
- ADHD (1 shared issues)
-
- Angelini (1 shared issues)
-
- anticholinergics (1 shared issues)
-
- AOP Orphan Pharmaceuticals AG (1 shared issues)
-
- AstraZeneca (1 shared issues)
-
- benzos (1 shared issues)
-
- bisphosphonates (1 shared issues)
-
- buspirone (1 shared issues)
-
- Carlat (1 shared issues)
-
- Carlat Report (1 shared issues)
-
- Daily Mail (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
Professor Kasper seems like as legitimate and respectable a researcher as you can get for these kinds of things: head of the Department of Psychiatry at the University of Vienna, chair of the World Psychiatric Association’s pharmacology branch, editor of three good journals, various important and influential papers. Sure, he’s gotten “grants/research support, consulting fees and/or honoraria” from Schwabe. But he’s also gotten money from “Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, KRKA-Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre . . . and Servier”, and you don’t see him writing nearly as many glowing papers about their drugs. High-level academic psychiatrists academics are usually working with a bunch of drug companies and getting paid for that work, and this isn’t usually considered disqualifying to their credibility.
Inline links: Professor Kasper
Recently a Danish team affiliated with the pharma company Lundbeck discovered an entirely new way to get into fights about this. I found their paper, Determining maximal achievable effect sizes of antidepressant therapies in placebo-controlled trials, more enlightening than most other writing on this issue. They ask: what if the skeptics’ preferred effect size number is impossible to reach?